Oncology Drug Articles & Analysis: This-Year
2 articles found
Many oncology drugs have been abandoned by pharmaceutical companies due to poor performance in phase I, II, or III clinical trials. These drugs represent untapped potential treatments for indications outside of those initially investigated. With research and development costs for a single new drug estimated between $2–3 ...
This article explores the mechanisms, benefits, challenges, and future prospects of PEGylation in drug development. Mechanism of PEGylation PEGylation involves the covalent or non-covalent attachment of PEG—a synthetic, hydrophilic polymer—to a drug molecule. ...